{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:11:29Z","timestamp":1785946289098,"version":"3.56.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Topical therapies are a mainstay of treatment for mild psoriasis and may be a useful adjunct in treatment of moderate-to-severe psoriasis. This review summarizes recent advances in topical therapies for psoriasis and currently available treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Topical aryl hydrocarbon receptor modulators (tapinarof) and topical phosphodiesterase-4 inhibitors (roflumilast) have been proven effective in randomized controlled trials for psoriasis. Although topical JAK inhibitors have also been studied, none are currently licensed for treatment of psoriasis. Topical corticosteroids and vitamin D analogues remain the most commonly used and widely available topical treatments for psoriasis. Cost may limit use of novel topical agents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Although the novel topical agents tapinarof and roflumilast are licensed for treatment of psoriasis by the FDA in the United States, they have not yet been licensed in Europe, and it remains to be seen whether they will be limited by cost.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001018","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T10:00:09Z","timestamp":1713866409000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["An update on topical therapies for psoriasis"],"prefix":"10.1097","volume":"36","author":[{"given":"Emily K.","family":"Pender","sequence":"first","affiliation":[{"name":"St Vincent's University Hospital, Elm Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"St Vincent's University Hospital, Elm Park"},{"name":"Charles Institute of Dermatology, University College Dublin, Belfield, Dublin 4, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"R3-20250526","first-page":"CD011571","article-title":"Antistreptococcal interventions for guttate and chronic plaque psoriasis","volume":"3","author":"Dupire","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-20250526","first-page":"93","article-title":"Erythrodermic psoriasis: pathophysiology and current treatment perspectives","volume":"6","author":"Singh","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"E1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis Pathogenesis and Treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"251.e19","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Academy Dermatol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","article-title":"Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus","volume":"81","author":"Rigopoulos","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br J Dermatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"a015354","DOI":"10.3390\/ijms18112427","article-title":"Treatment Approaches to Moderate to Severe Psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/24755303231160683","article-title":"Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities","volume":"8","author":"Blauvelt","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s13555-021-00523-x","article-title":"Nail psoriasis: a review of effective therapies and recommendations for management","volume":"11","author":"Hadeler","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40257-021-00649-w","article-title":"New topical therapies for psoriasis","volume":"23","author":"Le","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1684\/ejd.2018.3302","article-title":"Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study","volume":"28","author":"Griffiths","year":"2018","journal-title":"Eur J Dermatol"},{"key":"R17-20250526","first-page":"428","article-title":"Calcitriol 3\u200amicrog\/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies","volume":"6","author":"Lebwohl","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"adv00890","DOI":"10.2340\/actadv.v103.6525","article-title":"Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review","volume":"103","author":"Amiri","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"R19-20250526","first-page":"1280","article-title":"Tazarotene revisited: safety and efficacy in plaque psoriasis and its emerging role in treatment strategy","volume":"17","author":"Tanghetti","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215424","article-title":"Aryl hydrocarbon receptor in atopic dermatitis and psoriasis","volume":"20","author":"Furue","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/exd.12350","article-title":"Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases","volume":"23","author":"Kim","year":"2014","journal-title":"Exp Dermatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/pr.113.007823","article-title":"Aryl hydrocarbon receptor control of adaptive immunity","volume":"65","author":"Quintana","year":"2013","journal-title":"Pharmacol Rev"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jdv.18925","article-title":"Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N Engl J Med"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial","volume":"87","author":"Strober","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-022-01748-6","article-title":"Tapinarof cream 1%: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"R28-20250526","first-page":"21","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"11","author":"Milakovic","year":"2021","journal-title":"Psoriasis (Auckl)"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"734","DOI":"10.36849\/JDD.2020.5370","article-title":"Roflumilast cream improves signs and symptoms of plaque psoriasis: results from a phase 1\/2a randomized, controlled study","volume":"19","author":"Papp","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of roflumilast cream for chronic plaque psoriasis","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N Engl J Med"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40257-022-00739-3","article-title":"Effect of roflumilast cream (ARQ-151) on itch and itch-related sleep loss in adults with chronic plaque psoriasis: patient-reported itch outcomes of a phase 2b trial","volume":"24","author":"Stein Gold","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 Randomized Clinical Trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/bjd\/ljad182","article-title":"Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study","volume":"189","author":"Kircik","year":"2023","journal-title":"Br J Dermatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"283617","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis","volume":"2014","author":"Hsu","year":"2014","journal-title":"J Immunol Res"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bjd\/ljad098","article-title":"Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study","volume":"189","author":"Landis","year":"2023","journal-title":"Br J Dermatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:09Z","timestamp":1748294169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001018","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}